Cystinosis Foundation Ireland to Host Event June 27-28, 2008
NOVATO, Calif., June 23 /CNW/ -- Raptor Pharmaceuticals Corp. ("Raptor"
or the "Company") (OTC Bulletin Board: RPTP), today announced that Ted Daley,
President of Raptor's clinical division, will present at the Cystinosis
Foundation Ireland's 5th International Cystinosis Conference to be held June
27-28, 2008 at the Hilton Hotel, Dublin City, Charlemont Place, Dublin 2, in
World experts in the field of Cystinosis and families affected by
Cystinosis attending the event can discuss Mr. Daley's presentation between
3:45pm and 5:30pm in the conference hall on Friday, June 27, 2008, during the
poster and round table session of the conference.
For more information on this event please visit: http://www.cystinosis.ie.
Cystinosis is an inborn metabolic error characterized by abnormal
transport of cystine, an amino acid, out of the lysosomes. Symptom onset
typically occurs within the first year after birth, when cystine crystals
accumulate in various tissues and organs, including the kidneys, brain, liver,
thyroid, pancreas, muscles and eyes. Failure to treat the disease can cause
serious health consequences, including renal failure and resultant kidney
transplant, growth failure, rickets, photophobia and blindness.
In collaboration with the University of California, San Diego ("UCSD"),
supported by the Cystinosis Research Foundation ("CRF"), Raptor is developing
a delayed-release version of cysteamine bitartrate ("DR Cysteamine") for the
treatment of Cystinosis. Cysteamine bitartrate, a cystine-depleting agent, is
the only Cystinosis treatment approved for sale by the U.S. Food and Drug
Administration ("FDA") and the European Medicines Agency ("EMEA").
Although it can delay or prevent kidney transplant in Cystinosis
patients, the current formulation of cysteamine bitartrate is not well
tolerated by many Cystinosis patients, who experience severe gastrointestinal
distress from the drug. Additionally, the strict, current four times daily
dose regimen means that Cystinosis patients must be awakened every night to
take the medicine. These side effects and frequent dosing requirements result
in non-compliance or skipped doses for many patients. Studies have shown that
non-compliance with the current cysteamine bitartrate dose regimen can lead to
deteriorating kidney function and other complications.
Based on safety and efficacy studies performed at UCSD, Raptor believes
that Cystinosis patients could benefit from a more convenient and superior
treatment alternative utilizing DR Cysteamine.
Mr. Daley stated, "We are pleased to have been invited to present at the
International Cystinosis Conference. I look forward to sharing results from
studies performed at UCSD with a delayed-release form of cysteamine bitartrate
which suggest that DR Cysteamine has the potential to become a safer and more
effective treatment option for Cystinosis patients and could resolve current
non-compliance issues prevalent in this patient population. These findings
are supported by the Cystinosis Research Foundation's survey results on the
challenges patients face in complying with the current drug's frequent dosing
requirements, which I also plan to present. Our goal is to improve the
quality of life of the Cystinosis patients and their families."
Raptor plans to initiate an expanded study of its final proprietary DR
Cysteamine formulation in collaboration with the UCSD clinical researchers in
About Cystinosis Foundation Ireland and the International Cystinosis
Cystinosis Foundation Ireland was set up in 2003 to support Cystinosis
patients and their families. The goal of the Foundation is to raise awareness
about Cystinosis and support research through its fundraising efforts. The
International Cystinosis Conference takes place every two years in Europe. In
addition to world experts in the field of Cystinosis, the conference attracts
Cystinosis patients and their families who want to hear the latest research in
this rare lysosomal storage disease.
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. ("Raptor") consists of a preclinical
division and a clinical division, which together form a continuous set of
specialized competencies to develop Raptor's pipeline of drug product
candidates from early stage to clinical stage through to commercialization.
Raptor's preclinical division bioengineers novel drug candidates and
drug-targeting platforms derived from the human receptor-associated protein
("RAP") and related proteins, while Raptor's clinical division advances
clinical-stage product candidates towards marketing approval and
commercialization. Raptor's initial clinical programs include the treatment of
aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and
non-alcoholic steatohepatitis ("NASH").
Raptor preclinical programs target cancer, neurodegenerative disorders
and infectious diseases. HepTide(TM) is designed to utilize engineered
RAP-based peptides conjugated to drugs to target delivery to the liver to
potentially treat primary liver cancer and hepatitis. NeuroTrans(TM)
represents engineered RAP peptides created to target receptors in the brain
and are currently undergoing preclinical evaluation at Stanford University for
their ability to enhance the transport of therapeutics across the blood-brain
Raptor's clinical division executes the clinical development of: 1)
Raptor's internally developed product candidates; 2) new chemical entities
in-licensed for mid-to-late stage clinical development; 3) currently approved
drugs with potential in additional indications; and 4) treatments that may be
repurposed or reformulated for greater efficacy or convenience for their
currently approved indications.
Raptor currently has eight patent applications under review in the U.S.
and abroad, as well as four provisional patent applications in the U.S. In
addition, Raptor has licensed two provisional patent applications from
Washington University and one patent application and one provisional patent
application from UC San Diego.
For additional information, please visit www.raptorpharma.com.
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. These statements
relate to future events or our future results of operation or future financial
performance, including, but not limited to the following statements: Raptor's
ability to develop DR Cysteamine for the treatment of Cystinosis; Raptor's
ability to formulate and manufacture DR Cysteamine in clinical quantities to
support clinical trials; DR Cysteamine's ability to reduce side effects,
reduce dosage and/or frequency of dosing in Cystinosis patients; and DR
Cysteamine's ability to improve the quality of life of families affected by
Cystinosis. These statements are only predictions and involve known and
unknown risks, uncertainties and other factors, which may cause our actual
results to be materially different from these forward-looking statements.
Factors which may significantly change or prevent our forward looking
statements from fruition include that we may be unsuccessful in developing any
products or acquiring products; that our technology may not be validated as we
progress further and our methods may not be accepted by the scientific
community; that we are unable to retain or attract key employees whose
knowledge is essential to the development of our products; that unforeseen
scientific difficulties develop with our process; that our patents are not
sufficient to protect essential aspects of our technology; that competitors
may invent better technology; that our products may not work as well as hoped
or worse, that our products may harm recipients; and that we may not be able
to raise sufficient funds for development or working capital when we require
it. As well, our products may never develop into useful products and even if
they do, they may not be approved for sale to the public. We caution readers
not to place undue reliance on any such forward-looking statements, which
speak only as of the date they were made. Certain of these risks,
uncertainties, and other factors are described in greater detail in our
filings from time to time with the Securities and Exchange Commission (the
"SEC"), which we strongly urge you to read and consider, including our
Registration Statement on Form SB-2, as amended, that was declared effective
on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on
November 14, 2007; and our Form 10-QSB filed with the SEC on April 15, 2008,
all of which are available free of charge on the SEC's web site at
http://www.sec.gov. Subsequent written and oral forward-looking statements
attributable to us or to persons acting on our behalf are expressly qualified
in their entirety by the cautionary statements set forth in our reports filed
with the SEC. We expressly disclaim any intent or obligation to update any
For more information, please contact:
The Ruth Group
Sara Ephraim (investors) Janine McCargo (media)
(646) 536-7002 (646) 536-7033
For further information:
For further information: Investors, Sara Ephraim, +1-646-536-7002,
email@example.com, or Media, Media, Janine McCargo, +1-646-536-7033,
firstname.lastname@example.org Web Site: http://www.raptorpharma.com